Clinical Laserthermia Systems AB (CLSB)

Clinical Laserthermia Systems AB (CLSB) is a Swedish medical technology company based in Lund, specializing in minimally invasive laser-based treatment systems for cancer and neurosurgery. Their primary product, the TRANBERG® Thermal Therapy System, includes the Thermoguide™ Workstation and sterile disposables for precise laser ablation of soft tissue, cancer tumors, and drug-resistant epilepsy. This system allows for focal therapy, targeting and destroying diseased tissue while preserving healthy surrounding tissue, which helps reduce side effects and recovery times. CLSB's technology is utilized mainly for treating low to intermediate prostate cancer, brain tumors, and epileptic foci. They are also developing immunostimulating interstitial laser thermotherapy (imILT®), which combines laser ablation with immune system activation to potentially treat tumors in various organs. The TRANBERG® system features real-time monitoring and control for enhanced treatment accuracy and safety. CLSB is publicly traded on the Nasdaq First North Growth Market and has subsidiaries in Germany, the US, and Singapore to support its global operations.

• Employees 17
• Founded 2006
• Annual Revenue $1709000